Equity Overview
Price & Market Data
Price: $0.80
Daily Change: -$0.20 / 25.00%
Daily Range: $0.785 - $1.89
Market Cap: $4,388,179
Daily Volume: 94,980,621
Performance Metrics
1 Week: -13.88%
1 Month: 15.58%
3 Months: 15.58%
6 Months: -33.95%
1 Year: -74.97%
YTD: -46.76%
Company Details
Employees: 8
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor that is in phase 1a/b clinical trial for the treatment of ulcerative colitis, as well as under phase 1a clinical trial for the treatment of fibrostenotic crohn's disease. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company is headquartered in Carlsbad, California.